Testing a new drug for Alzheimer's disease with eye scans
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests an investigational drug called AMDX-2011P for people with Alzheimer's disease. It looks at whether the drug affects the retina, which may be linked to brain changes in Alzheimer's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed Alzheimer's diagnosis with a positive PET brain scan showing amyloid beta plaques.
- You must agree to a genetic test for the APOE gene.
- You must be able to keep your eyes still for detailed retinal imaging.
- You cannot have glaucoma or be suspected of having it in either eye.
- You cannot have certain forms of age-related macular degeneration in either eye.
- You cannot have heart rhythm problems or certain lab abnormalities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study uses detailed eye imaging (an eye scan) to look for signs related to probable Alzheimer’s disease and mild dementia. It may help researchers understand whether eye scans can reflect brain changes and improve detection.
This study uses a special dye and imaging to see if certain immune cells (dendritic cells) travel to the retina. It aims to understand how the immune system might play a role in dry age-related macular degeneration, mild cognitive impairment due to Alzheimer's, or early Alzheimer's disease.
This study tests an investigational drug, ARO-MAPT-SC, which targets a protein involved in Alzheimer's disease. It is for people with early Alzheimer's to see if the drug is safe and can slow the disease.
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.